U.S., July 18 -- ClinicalTrials.gov registry received information related to the study (NCT07070674) titled 'A Phase Ib Clinical Study of AC-003 Capsules in Subjects With Steroid-refractory aGVHD.' on June 30.
Brief Summary: The study was an open-label, single-arm, dose-escalation, Phase Ib, multi-center study to investigate safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of AC-003 in patients with grade II-IV SR-aGVHD.
Study Start Date: July 25, 2024
Study Type: INTERVENTIONAL
Condition:
Acute Graft-versus-Host Disease
Intervention:
DRUG: AC-003
AC-003 capsules will be administered orally.
Recruitment Status: RECRUITING
Sponsor: Accro Bioscience (Suzhou) Limited
Published by HT Digital Content Services with p...